Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Benitec Biopharm Ads (BNTC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 24,111
  • Shares Outstanding, K 10,260
  • Annual Sales, $ 2,950 K
  • Annual Income, $ -18,050 K
  • 36-Month Beta 3.31
  • Price/Sales 68.58
  • Price/Cash Flow 0.00
  • Price/Book 1.43

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.25 +5.33%
on 05/18/17
3.16 -25.00%
on 05/05/17
-0.27 (-10.23%)
since 04/21/17
3-Month
2.24 +5.80%
on 03/22/17
5.48 -56.75%
on 04/04/17
-0.22 (-8.49%)
since 02/22/17
52-Week
1.20 +97.50%
on 07/06/16
5.48 -56.75%
on 04/04/17
+0.72 (+43.64%)
since 05/20/16

Most Recent Stories

More News
How These Biotech Stocks are Faring? -- Cymabay Therapeutics, Benitec Biopharma, Sage Therapeutics, and Catalyst Biosciences

On Tuesday, April 25, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Eight out of nine sectors ended Tuesday's trading session in bullish...

BNTC : 2.37 (+0.85%)
CBAY : 3.91 (unch)
SAGE : 66.89 (+2.06%)
CBIO : 3.90 (-3.23%)
BNIKF : 0.1392 (+3.88%)
Today's Research Reports on Biotech Stocks to Watch: Benitec Biopharma and Paratek Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / April 5, 2017 / On Tuesday, Benitec Biopharma and Paratek Pharmaceuticals both reported FDA trial results and investors moved quickly to take advantage of the good news. Volume...

BNTC : 2.37 (+0.85%)
PRTK : 21.35 (-0.93%)
BNIKF : 0.1392 (+3.88%)
Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma

On Thursday, March 23, 2017, the NASDAQ Composite ended the trading session at 5,817.69, down 0.07%; the Dow Jones Industrial Average edged 0.02% lower, to finish at 20,656.58; and the S&P 500 closed at...

BNTC : 2.37 (+0.85%)
BDSI : 2.35 (-4.08%)
SAGE : 66.89 (+2.06%)
OGXI : 0.36 (+2.86%)
BNIKF : 0.1392 (+3.88%)
M&A Activity Could Kick Start Biotech Industry's Recovery in 2017: Today's Report on Benitec and Protalix

NEW YORK, NY / ACCESSWIRE / February 3, 2017 / The Biotech Industry has experienced some steep losses in recent years, but has begun to show some signs of stabilization in 2017. The Industry was home to...

BNTC : 2.37 (+0.85%)
XBI : 69.61 (+0.68%)
Bioblast (ORPN) SCA3 Drug Favorable in Phase IIa Study

Bioblast (ORPN) announced results from a phase IIa study on trehalose for the treatment of patients with spinocerebellar ataxia type 3.

ANIK : 46.81 (-0.47%)
ORPN : 0.43 (-17.31%)
BNTC : 2.37 (+0.85%)
SCMP : 10.65 (+0.95%)
Blog Coverage Benitec Biopharma Secures Orphan Drug Designation for its Product Treating Patients with Oculopharyngeal Muscular Dystrophy

Upcoming AWS Coverage on Biogen

BNTC : 2.37 (+0.85%)
BNIKF : 0.1392 (+3.88%)
BIIB : 250.04 (-0.02%)
Benitec Stock Up on Orphan Drug Status for BB-301 in EU

Benitec (BNTC) announced that its proposed candidate, BB-301, received Orphan Drug Designation in the EU for the treatment of ocularpharyngeal muscular dystrophy.

ANIK : 46.81 (-0.47%)
ORPN : 0.43 (-17.31%)
BNTC : 2.37 (+0.85%)
SCMP : 10.65 (+0.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B,...

See More

Support & Resistance

2nd Resistance Point 2.70
1st Resistance Point 2.54
Last Price 2.37
1st Support Level 2.28
2nd Support Level 2.18

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.